| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.cian.co | |
| Market Cap | 39.49 Cr. | |
| Enterprise Value(EV) | 107.51 Cr. | 2021-03 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | -2.21 | Trailing Twelve Months Ending 2022-03 |
| Price-Earning Ratio (PE) | - | Trailing Twelve Months Ending 2022-03 |
| Industry PE | 31.91 | Trailing Twelve Months Ending 2022-03 |
| Book Value / Share | 22.21 | Trailing Twelve Months Ending 2022-03 |
| Price to Book Value | 0.71 | Calculated using Price: 15.80 |
| Dividend Yield | 0.00 | Period Ending 2021-03 |
| No. of Shares Subscribed | 2.50 Cr. | 24,995,764 Shares |
| FaceValue | 10 | |
| Company Profile | ||
| The Company develops, manufactures and commercializes pharmaceutical products including sales, marketing, quality assurance, distribution, compliance and regulatory aspects under 12 therapeutic segments like Orthopaedics, Gynaecology, Paediatrics, Cardiac, Diabetic, Dermatology, Pain Management, Antibiotics, Neuro, Critical Care, Gastro-Intestinal and Nutraceuticals, along with 10 sales division focused on developing and growing its engagements in specialist and super specialist division. The company works under different business models like Brand Business, Export, Third Party Manufacturing and Government Supplies. The Company manufactures innovative products comprising of Tablets, Capsules, Liquid Orals, Ointments, Creams, Lotions, Gels and Sachet. The Company has special licence for manufacturing veterinary products for client like SAVAvet and Venky's. | ||
| 1 Day |
|
-4.82% |
| 1 Week |
|
-12.22% |
| 1 Month |
|
-13.90% |
| 3 Month |
|
-33.61% |
| 6 Month |
|
-22.74% |
| 1 Year |
|
-24.76% |
| 2 Year |
|
+23.44% |
| 5 Year |
|
|
| 10 Year |
|
| 2 years | 2020-03 | 2021-03 | |
| Return on Equity (%) | -7.54 | 0.10 | |
| Return on Capital Employed (%) | 3.00 | 6.99 | |
| Return on Assets (%) | -2.42 | 0.03 |
| Particulars | 2 years | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. |
| Shh. Funds | 58 | 58 | |
| Non Curr. Liab. | 50 | 41 | |
| Curr. Liab. | 48 | 58 | |
| Minority Int. | |||
| Equity & Liab. | 157 | 157 | |
| Non Curr. Assets | 94 | 88 | |
| Curr. Assets | 54 | 63 | |
| Misc. Exp. not W/O | 8 | 5 | |
| Total Assets | 157 | 157 |
| Particulars | 2 years | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. |
| Net Sales | 57 | 74 | |
| Other Income | 1 | 0 | |
| Total Income | 58 | 74 | |
| Total Expenditure | -50 | -62 | |
| PBIDT | 8 | 12 | |
| Interest | -7 | -8 | |
| Depreciation | -4 | -3 | |
| Taxation | 0 | -1 | |
| Exceptional Items | 0 | 0 | |
| PAT | -4 | 0 | |
| Minority Interest | |||
| Share Associate | |||
| Other Related Items | |||
| Consolidated Net Profit | -4 | 0 | |
| Adjusted EPS | -2 | 0 |
| Particulars | 2 years | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. |
| Cash Fr. Operatn. | -7 | 6 | |
| Cash Fr. Inv. | -27 | 3 | |
| Cash Fr. Finan. | 36 | -10 | |
| Net Change | 1 | -1 | |
| Cash & Cash Eqvt | 3 | 2 |
|
Fri, 07 Oct 2022
Quarterly Disclosures By Listed Entities Of Defaults On Payment Of Interest/ Repayment Of Principal Amount On Loans From Banks / Financial Institutions And Unlisted Debt Securities Quarterly Disclosures by listed entities of defaults on payment of interest/ repayment of principal amount on loans from banks / financial institutions and unlisted debt securities |
|
Sat, 01 Oct 2022
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report DECLARATION OF REMOTE E- VOTING AND POLL VOTING RESULTS IN COMPLIANCE WITH REGULATION 44 (3) OF SEBI (LODR) REGULATIONS 2015. |
|
Fri, 30 Sep 2022
Shareholder Meeting / Postal Ballot-Outcome of AGM CORPORATE ANNOUNCEMENT FOR OUTCOME OF 19TH ANNUAL GENERAL MEETING FOR THE FINANCIAL YEAR 2021-22 HELD ON FRIDAY 30TH DAY OF SEPTEMBER 2022. |
| Thu, 06 Oct 2022 |
High Delivery Percentage
|
Close Crossing Last Month Low
|
Opening at Low
|
Closing Below Previous Low
|
High Decrease 1 Month
|
Equities
M.F.
Sectors